Header Logo

VICTOR RIVERA

TitleDistinguished Emeritus Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Neurology
Address7200 CAMBRIDGE
Houston, TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Rojas JI, Gracia F, Parciak T, Alonso R, Becker J, Trevi?o-Frenk I, Alonso-Serena M, Giunta D, Abad P, Carnero-Contentti E, Carr? A, Correa-D?az EP, Correale J, Cristiano E, Flores J, Fruns M, Galleguillos L, Garcea O, Hamuy F, Lana-Peixoto M, Navas C, Pappais-Alvarenga R, Patrucco L, Rivera V, Tenembaum S, Ysrraelit MC, Peeters LM. [Core data set for real world data in multiple sclerosis: customization for latin america from a global task force recommendation]. Rev Neurol. 2024 Apr 01; 78(7):185-197. PMID: 38502167.
      Citations:    Fields:    Translation:Humans
    2. Rivera VM. Neuromyelitis Optica Spectrum Disorder: Redefining an Old Disease. Present and Future Challenges. J Integr Neurosci. 2023 Oct 18; 22(6):139. PMID: 38176944.
      Citations:    Fields:    Translation:Humans
    3. Liu C, Leighow SM, McIlroy K, Lu M, Dennis KA, Abello K, Brown DJ, Moore CJ, Shah A, Inam H, Rivera VM, Pritchard JR. Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing. Cell Rep Med. 2023 10 17; 4(10):101227. PMID: 37852183; PMCID: PMC10591048.
      Citations:    Fields:    Translation:Humans
    4. Avila M, Tan Y, Hernandez R, Zuberi H, Rivera VM. Correction to: Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Onset Following Acute COVID-19 Infection, a Case Series. Neurol Ther. 2023 Apr; 12(2):701. PMID: 36821074; PMCID: PMC9948788.
      Citations:    
    5. Avila M, Hernandez R, Zuberi H, Rivera VM, Tan Y. Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Onset Following Acute COVID-19 Infection, a Case Series. Neurol Ther. 2023 Feb; 12(1):319-327. PMID: 36399224; PMCID: PMC9672646.
      Citations: 3     
    6. George S, von Mehren M, Fletcher JA, Sun J, Zhang S, Pritchard JR, Hodgson JG, Kerstein D, Rivera VM, Haluska FG, Heinrich MC. Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers. Clin Cancer Res. 2022 04 01; 28(7):1268-1276. PMID: 35091442; PMCID: PMC9531534.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Parajeles-Vindas A, Weiser R, Santos B, Candelario A, Benzadon A, Araujo P, Larreategui M, Monterrey-Alvarez P, Sanabria-Castro A, Miranda-Loria G, Rivera LIP, Leal IO, Thompson A, Zepeda C, Van Sijtveld I, Rivera VM, Gracia F, Ram?rez D, D?az A, D?az de la F? A, S?nchez NER, Escobar RC, Valle LAG, Valderrama C, Carrillo G, Gracia K, V?zquez-C?spedes J, Carazo-C?spedes K, Balmaceda-Meza A, Salinas LCR, Torres EL, Pereira DE, L?pez CA, Valse EAC, Urbina KZC, Urrutia MA, Armien B. Neuromyelitis Optica Spectrum Disorder in Central America and the Caribbean: A Multinational Clinical Characterization Study. Neurol Int. 2022 Mar 17; 14(1):284-293. PMID: 35324579; PMCID: PMC8952282.
      Citations:    
    8. Rivera VM. Editorial of Special Issue "Multiple Sclerosis: Diagnosis and Treatment II". Biomedicines. 2021 Nov 03; 9(11). PMID: 34829833; PMCID: PMC8615709.
      Citations:    
    9. Rivera VM, Hamuy F, Rivas V, Gracia F, Bichuetti DB, Marques VD, Soto A, Bertado B, Ramirez DA, Ciampi E, Lana-Peixoto MA, Zarco L, Becker J, Lopez E, Carnero Contentti E, Diaz A, Playas G, Rojas E, Sato D, Correale J, Barboza A, Monterrey P, Candelario A, Tavolini DR, Raggio JV, Ramirez NE, Skromne E, Portillo LL, Canabal AP, Weiser R, Sirias V, Quiroz JCD, Garcia LA, Abad-Herrera P, Rojas JI, Villa AM, Frenk IT, Galleguillos L, Qui?ones J, Capar?-Zamalloa C, Rodr?guez E, Sinay V, Armas E, Benzad?n A, Correa-Diaz EP, Fleitas CV, Molina O, Soto I, C?spedes JV, Parajeles A, Pujol BS, Diaz de la Fe A, Alonso R, Bola?a C, Guzman MK, Carr? A, Gamarra OG, Rodriguez LC, Ordo?ez L, Calder?n RF, Cornejo EA, Hern?ndez M, Cede?o CO, Mart?nez J. Status of the neuromyelitis optica spectrum disorder in Latin America. Mult Scler Relat Disord. 2021 Aug; 53:103083. PMID: 34171682.
      Citations: 2     Fields:    Translation:Humans
    10. Abad P, Becker J, Carra A, Correale J, Diaz AJ, Fruns M, Giachello SM, Gracia F, Hamuy VF, Henestroza PR, Navas C, Rivera VM, Ysrraelit MC, Alonso Serena M, on behalf research priorities LACTRIMS working group, Rojas JI, Carnero Contentti E, Aguayo A, Alonso R, Bauer J, Bustos AK, Carcamo CA, Correa Diaz EP, Cristiano E, Fernandez Liguori N, Flores J, Garcea O, Godoy MD, Navarra JA, Patrucco L, Perez Bruno M, Prato AS, Rosa Martinez AR, Vanotti S, Vazquez M, Vizcarra D. Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care: Research priorities in MS in LATAM. Mult Scler Relat Disord. 2021 Aug; 53:103038. PMID: 34090128.
      Citations:    Fields:    Translation:HumansCells
    11. Rivera VM, Gracia F, D?az A. [Therapeutic attitudes towards multiple sclerosis in Central America and the Caribbean facing the SARS-CoV-2 pandemia]. Neurologia (Engl Ed). 2020 Nov - Dec; 35(9):705-706. PMID: 32893070; PMCID: PMC7543929.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    12. Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020 05 26; 10(5):61. PMID: 32457305; PMCID: PMC7250857.
      Citations: 3     Fields:    Translation:HumansCells
    13. Fisher KS, Cuascut FX, Rivera VM, Hutton GJ. Current Advances in Pediatric Onset Multiple Sclerosis. Biomedicines. 2020 Mar 28; 8(4). PMID: 32231060; PMCID: PMC7235875.
      Citations: 5     
    14. Rivera VM. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk? Neurol Ther. 2019 Dec; 8(2):177-184. PMID: 31313222; PMCID: PMC6858917.
      Citations: 1     
    15. Castillo-Mart?nez D, Rivera V, Mouneu-Ornelas N, Mart?nez-Mart?nez LA, Jim?nez-Rojas V, M?rquez-Velasco R, Amezcua-Guerra LM. Levels of anti-M?llerian hormone in premenopausal women with the antiphospholipid syndrome and its association with the risk of clinical complications. Lupus. 2019 Mar; 28(3):427-431. PMID: 30717622.
      Citations:    Fields:    Translation:Humans
    16. Rivera VM. Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines. Biomedicines. 2018 Nov 30; 6(4). PMID: 30513578; PMCID: PMC6316848.
      Citations: 4     
    17. Schmitt MW, Pritchard JR, Leighow SM, Aminov BI, Beppu L, Kim DS, Hodgson JG, Rivera VM, Loeb LA, Radich JP. Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res. 2018 11 01; 24(21):5321-5334. PMID: 30042204; PMCID: PMC6214777.
      Citations: 7     Fields:    Translation:HumansCells
    18. Gozgit JM, Chen TH, Song Y, Wardwell S, Wang F, Cai J, Li H, Edgren H, Rivera VM, Pritchard J. RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. Oncotarget. 2018 Jul 03; 9(51):29654-29664. PMID: 30038711; PMCID: PMC6049858.
      Citations: 10     Fields:    
    19. Cortes JE, Kim DW, Pinilla-Ibarz J, Paquette R, Chuah C, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Baccarani M, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM, le Coutre PD, Nicolini FE, Rea D, M?ller MC, Guilhot F. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404. PMID: 29567798; PMCID: PMC6071555.
      Citations: 119     Fields:    Translation:HumansCellsCTClinical Trials
    20. Rivera VM. Multiple sclerosis as a universal disease and the challenges to immigrants in high prevalence countries. Eur J Neurol. 2018 04; 25(4):612-613. PMID: 29341368.
      Citations:    Fields:    Translation:Humans
    21. Rivera VM. Multiple Sclerosis in Latin Americans: Genetic Aspects. Curr Neurol Neurosci Rep. 2017 Aug; 17(8):57. PMID: 28639238.
      Citations: 3     Fields:    Translation:Humans
    22. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. PMID: 27836716.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    23. Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang WS, Liu S, Zou D, Wang Y, Mohemmad Q, Jang HG, Ye E, Narasimhan N, Wang F, Miret J, Zhu X, Clackson T, Dalgarno D, Shakespeare WC, Rivera VM. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016 Nov 15; 22(22):5527-5538. PMID: 27780853.
      Citations: 103     Fields:    Translation:HumansCells
    24. Parra-Bernal MC, Rivera-Olmos VM. [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences]. Rev Med Inst Mex Seguro Soc. 2016 Sep-Oct; 54(5):626-34. PMID: 27428345.
      Citations: 3     Fields:    Translation:HumansAnimals
    25. Lipton JH, Chuah C, Rosti G, Simpson D, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW, EPIC investigators, Guerci-Bresler A, Assouline S, Etienne G, Nicolini FE, le Coutre P, Guilhot F, Hochhaus A. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21. PMID: 27083332.
      Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
    26. Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. 2016 Apr 14; 127(15):1870-80. PMID: 26773037; PMCID: PMC4832506.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    27. Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hughes TP, Rivera VM, Branford S, M?ller MC, Hochhaus A. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12. PMID: 26603839; PMCID: PMC4760131.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    28. Baker T, Nerle S, Pritchard J, Zhao B, Rivera VM, Garner A, Gonzalvez F. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget. 2015 Oct 20; 6(32):32646-55. PMID: 26360609; PMCID: PMC4741719.
      Citations: 33     Fields:    Translation:HumansCells
    29. Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15; 20(22):5745-5755. PMID: 25239608; PMCID: PMC4233175.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    30. Rivera VM, Medina MT, Duron RM, Macias MA. Multiple sclerosis care in Latin America. Neurology. 2014 May 06; 82(18):1660-1. PMID: 24799516; PMCID: PMC4013811.
      Citations: 11     Fields:    Translation:Humans
    31. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators, M?ller MC. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 07; 369(19):1783-96. PMID: 24180494; PMCID: PMC3886799.
      Citations: 353     Fields:    Translation:HumansCTClinical Trials
    32. Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol. 2013 Jul 11; 13:80. PMID: 23841877; PMCID: PMC3710498.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    33. Soria-Cedillo IF, Velazquez-Quintana M, Rivera VM, Lemus-Carmona EA, Chiquete E, Mac?as-Islas MA, Baca-Muro VI. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg. 2013 Dec; 113(4):415-20. PMID: 23670405.
      Citations: 3     Fields:    Translation:Humans
    34. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May; 71(5):1315-23. PMID: 23468082.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    35. Abad P, Nogales-Gaete J, Rivera V, Cristiano E, Hamuy F, Oehninger C, Alvarenga RM, Tenembaum S, Grupo de Estudio de Esclerosis M?ltiple de Latinoam?rica Lactrims. [LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants]. Rev Neurol. 2012 Dec 16; 55(12):737-48. PMID: 23233142.
      Citations: 3     Fields:    Translation:Humans
    36. Mita MM, Poplin E, Britten CD, Tap WD, Rubin EH, Scott BB, Berk L, Rivera VM, Loewy JW, Dodion P, Haluska F, Sarantopoulos J, Mita A, Tolcher A. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Ann Oncol. 2013 Apr; 24(4):1104-11. PMID: 23211938.
      Citations: 14     Fields:    Translation:HumansAnimalsCTClinical Trials
    37. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88. PMID: 23190221; PMCID: PMC3777383.
      Citations: 272     Fields:    Translation:HumansCTClinical Trials
    38. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Clackson T, Rivera VM. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther. 2012 Mar; 11(3):690-9. PMID: 22238366.
      Citations: 141     Fields:    Translation:HumansAnimalsCells
    39. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012 01 01; 30(1):78-84. PMID: 22067397.
      Citations: 101     Fields:    Translation:HumansCTClinical Trials
    40. Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, Moran L, Mohemmad QK, Anjum R, Wang Y, Narasimhan NI, Dalgarno D, Shakespeare WC, Miret JJ, Clackson T, Rivera VM. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec; 78(6):999-1005. PMID: 22034911; PMCID: PMC3265718.
      Citations: 57     Fields:    Translation:HumansCells
    41. O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 2011 Nov 10; 118(19):5250-4. PMID: 21908430; PMCID: PMC3217407.
      Citations: 21     Fields:    Translation:HumansCells
    42. Stosic M, De Jesus P, McCarthy J, Hutton G, Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011 Aug 02; 77(5):505-7. PMID: 21775738.
      Citations: 2     Fields:    Translation:Humans
    43. Rivera VM. Tovaxin for multiple sclerosis. Expert Opin Biol Ther. 2011 Jul; 11(7):961-7. PMID: 21563876.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    44. Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011 Jun; 10(6):1028-35. PMID: 21482694; PMCID: PMC3236248.
      Citations: 60     Fields:    Translation:HumansAnimalsCells
    45. Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, Sandberg-Wollheim M, Traboulsee A, Verdun E, Rivera V. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord. 2011 Jan; 4(1):3-14. PMID: 21339904; PMCID: PMC3036958.
      Citations: 19     
    46. Avila-Ornelas J, Avila M, Stosic M, Robles L, Prieto PG, Hutton GJ, Rivera VM. The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. Int J MS Care. 2011; 13(2):91-3. PMID: 24453710; PMCID: PMC3882955.
      Citations: 3     
    47. Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T, Dalgarno DC, Zhu X. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des. 2011 Jan; 77(1):1-11. PMID: 21118377.
      Citations: 83     Fields:    Translation:AnimalsCells
    48. Perotti A, Locatelli A, Sessa C, Hess D, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L, Vigan? L. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol. 2010 Oct 20; 28(30):4554-61. PMID: 20855840.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    49. Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S, Romero J, Qi J, Chen I, Banda G, Lentini SP, Das S, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Zhou T, Commodore L, Narasimhan NI, Mohemmad QK, Iuliucci J, Rivera VM, Dalgarno DC, Sawyer TK, Clackson T, Shakespeare WC. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem. 2010 Jun 24; 53(12):4701-19. PMID: 20513156.
      Citations: 90     Fields:    Translation:AnimalsCells
    50. Cohen BA, Rivera VM. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010 Apr; 26(4):827-38. PMID: 20121658.
      Citations: 8     Fields:    Translation:Humans
    51. Rivera VM. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology. 2010 Mar 09; 74(10):864. PMID: 20211915.
      Citations:    Fields:    Translation:Humans
    52. Sessa C, Tosi D, Albanell J, Hess D, Maur M, Cresta S, Locatelli A, Angst R, Rojo F, Coceani N, Rivera VM, Berk L, Haluska F, Gianni L, Vigan? L. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol. 2010 Jun; 21(6):1315-1322. PMID: 19901013.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    53. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 06; 16(5):401-12. PMID: 19878872; PMCID: PMC2804470.
      Citations: 440     Fields:    Translation:HumansAnimalsCells
    54. Rivera VM. Multiple sclerosis in Latin America: reality and challenge. Neuroepidemiology. 2009; 32(4):294-5. PMID: 19246934.
      Citations: 7     Fields:    Translation:Humans
    55. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34. PMID: 19228743; PMCID: PMC3147153.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    56. Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, Zubair M, Rivera V. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford). 2009 Jan; 48(1):49-52. PMID: 18815156.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    57. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008 May 01; 14(9):2756-62. PMID: 18451242.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    58. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008 Jan 20; 26(3):361-7. PMID: 18202410.
      Citations: 91     Fields:    Translation:HumansCTClinical Trials
    59. Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Rivera V, Trojano M, Verheul F, Malkowski JP, P?hlau D. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006 Dec; 12(6):769-74. PMID: 17263005.
      Citations: 51     Fields:    Translation:Humans
    60. Skromne E, Rivera VM, Ontaneda D, Ordonez L. Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology. 2006 Jun 13; 66(11):1787-8; author reply 1787-8. PMID: 16769975.
      Citations: 1     Fields:    Translation:HumansCells
    61. Ordonez L, Skromne E, Ontaneda D, Rivera VM. Multiphasic disseminated encephalomyelitis, systemic lupus erythematosus and antiphospholipid syndrome. Clin Neurol Neurosurg. 2007 Jan; 109(1):102-5. PMID: 16624483.
      Citations: 2     Fields:    Translation:Humans
    62. Rivera VM. Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. Brain Inj. 2005 Aug 20; 19(9):725-7. PMID: 16195186.
      Citations:    Fields:    Translation:Humans
    63. Rivera VM. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2005 Jun 28; 64(12):2163. PMID: 15985607.
      Citations:    Fields:    Translation:Humans
    64. Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, Agius M, Bashir R, Collins TE, Herndon R, Kinkel P, Mikol DD, Picone MA, Rivera V, Tornatore C, Zwibel H. Identifying and treating patients with suboptimal responses. Neurology. 2004 Dec 28; 63(12 Suppl 6):S33-40. PMID: 15623669.
      Citations: 14     Fields:    Translation:Humans
    65. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, Clackson T, Wilson JM. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood. 2005 Feb 15; 105(4):1424-30. PMID: 15507527.
      Citations: 104     Fields:    Translation:AnimalsCells
    66. Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, Zhang JZ. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004 Oct; 10(5):499-506. PMID: 15471364.
      Citations: 8     Fields:    Translation:HumansCells
    67. O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 2004 Oct 15; 104(8):2532-9. PMID: 15256422.
      Citations: 44     Fields:    Translation:HumansCells
    68. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004 Jul; 152(1-2):126-39. PMID: 15223245.
      Citations: 15     Fields:    Translation:HumansCells
    69. Zang YC, Li S, Rivera VM, Hong J, Robinson RR, Breitbach WT, Killian J, Zhang JZ. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol. 2004 Apr 15; 172(8):5120-7. PMID: 15067096.
      Citations: 56     Fields:    Translation:HumansCells
    70. Hong J, Zang YCQ, Li S, Rivera VM, Zhang JZ. Ex vivo detection of myelin basic protein-reactive T cells in multiple sclerosis and controls using specific TCR oligonucleotide probes. Eur J Immunol. 2004 Mar; 34(3):870-881. PMID: 14991617.
      Citations: 5     Fields:    Translation:HumansCells
    71. Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB, Hogan N, Galetta S, Lee AG, Straumann D, Noseworthy J, Zee D, Corbett J, Corboy J, Rivera VM, Kramer PD. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology. 2003 Sep 23; 61(6):848-50. PMID: 14504338.
      Citations: 17     Fields:    Translation:Humans
    72. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 09; 61(5):602-11. PMID: 12963748.
      Citations: 31     Fields:    Translation:Humans
    73. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells. Int Immunol. 2003 Sep; 15(9):1073-80. PMID: 12917259.
      Citations: 5     Fields:    Translation:HumansCells
    74. Zang Y, Hong J, Robinson R, Li S, Rivera VM, Zhang JZ. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J Neuroimmunol. 2003 Apr; 137(1-2):144-53. PMID: 12667659.
      Citations: 7     Fields:    Translation:HumansCells
    75. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol. 2003 Feb; 53(2):189-97. PMID: 12557285.
      Citations: 91     Fields:    Translation:HumansCells
    76. Rivera VM. [Deciding on treatment in multiple sclerosis]. Rev Neurol. 2003 Jan 1-15; 36(1):80-5. PMID: 12577220.
      Citations:    Fields:    
    77. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Killian JM, Zhang JZ. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. J Virol. 2002 Jun; 76(12):6147-54. PMID: 12021348; PMCID: PMC136216.
      Citations: 18     Fields:    Translation:HumansCells
    78. Hong J, Tejada-Simon MV, Rivera VM, Zang YC, Zhang JZ. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler. 2002 May; 8(3):237-42. PMID: 12120696.
      Citations: 17     Fields:    Translation:HumansCells
    79. Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, Li S, Haykal H, Killian J, Zang YC. T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol. 2002 Feb; 249(2):212-8. PMID: 11985389.
      Citations: 18     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    80. Rivera VM, Cabrera JA. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology. 2001 Sep 11; 57(5):937-8. PMID: 11552042.
      Citations: 3     Fields:    Translation:Humans
    81. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol. 2001 Mar; 31(3):907-17. PMID: 11241296.
      Citations: 11     Fields:    Translation:HumansCells
    82. Rivera VM. [Neuroimaging in multiple sclerosis]. Rev Neurol. 2001 Feb 1-15; 32(3):283-5. PMID: 11310287.
      Citations:    Fields:    Translation:Humans
    83. Rivera VM. [Pharmacologic treatment of multiple sclerosis]. Rev Neurol. 2001 Feb 1-15; 32(3):285-8. PMID: 11310288.
      Citations: 1     Fields:    Translation:HumansCells
    84. Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis. Urology. 2001 Feb; 57(2):239-45. PMID: 11182328.
      Citations: 22     Fields:    Translation:Humans
    85. Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol. 2001 Jan 01; 112(1-2):174-80. PMID: 11108946.
      Citations: 13     Fields:    Translation:HumansCells
    86. Hong J, Zang YC, Tejada-Simon MV, Li S, Rivera VM, Killian J, Zhang JZ. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. J Immunol. 2000 Dec 15; 165(12):6858-64. PMID: 11120809.
      Citations: 8     Fields:    Translation:HumansCellsPHPublic Health
    87. Tejada-Simon MV, Zang YC, Yang D, Hong J, Li S, Singh RA, Van den Berg-Loonen E, Killian JM, Rivera VM, Zhang JZ. Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int Immunol. 2000 Dec; 12(12):1641-50. PMID: 11099303.
      Citations: 6     Fields:    Translation:HumansCells
    88. Rivera VM. [The treatment of multiple sclerosis with beta-interferon 1a]. Rev Neurol. 2000 Sep 1-15; 31(5):470-1. PMID: 11027100.
      Citations:    Fields:    Translation:Humans
    89. Zang YC, Samanta AK, Halder JB, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ. Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain. 2000 Sep; 123 ( Pt 9):1874-82. PMID: 10960051.
      Citations: 21     Fields:    Translation:HumansCells
    90. Zang YC, Yang D, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology. 2000 Aug 08; 55(3):397-404. PMID: 10932275.
      Citations: 9     Fields:    Translation:HumansCells
    91. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol. 2000 Apr 15; 164(8):4011-7. PMID: 10754292.
      Citations: 19     Fields:    Translation:HumansCellsPHPublic Health
    92. Zang YC, Hong J, Tejada-Simon MV, Li S, Rivera VM, Killian JM, Zhang JZ. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol. 2000 Mar; 30(3):908-13. PMID: 10741408.
      Citations: 12     Fields:    Translation:HumansCellsPHPublic Health
    93. Singh RA, Zang YC, Shrivastava A, Hong J, Wang GT, Li S, Tejada-Simon MV, Kozovska M, Rivera VM, Zhang JZ. Th1 and Th2 deviation of myelin-autoreactive T cells by altered peptide ligands is associated with reciprocal regulation of Lck, Fyn, and ZAP-70. J Immunol. 1999 Dec 15; 163(12):6393-402. PMID: 10586029.
      Citations: 3     Fields:    Translation:HumansCells
    94. Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, Zhang JZ. Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 1999 Nov 10; 53(8):1692-7. PMID: 10563614.
      Citations: 27     Fields:    Translation:HumansCells
    95. Hong J, Zang YC, Tejada-Simon MV, Kozovska M, Li S, Singh RA, Yang D, Rivera VM, Killian JK, Zhang JZ. A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol. 1999 Sep 15; 163(6):3530-8. PMID: 10477628.
      Citations: 11     Fields:    Translation:HumansCells
    96. Kil K, Zang YC, Yang D, Markowski J, Fuoco GS, Vendetti GC, Rivera VM, Zhang JZ. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J Neuroimmunol. 1999 Aug 03; 98(2):201-7. PMID: 10430053.
      Citations: 34     Fields:    Translation:HumansCells
    97. Zang YC, Kozovska MM, Hong J, Li S, Mann S, Killian JM, Rivera VM, Zhang JZ. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol. 1999 05; 29(5):1692-700. PMID: 10359124.
      Citations: 10     Fields:    Translation:HumansCells
    98. Zang YC, Kozovska M, Aebischer I, Li S, Boehme S, Crowe P, Rivera VM, Zhang JZ. Restricted TCR Valpha gene rearrangements in T cells recognizing an immunodominant peptide of myelin basic protein in DR2 patients with multiple sclerosis. Int Immunol. 1998 Jul; 10(7):991-8. PMID: 9701037.
      Citations: 1     Fields:    Translation:HumansCells
    99. Kozovska M, Zang YC, Aebischer I, Lnu S, Rivera VM, Crowe PD, Boehme SA, Zhang JZ. T cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: structural requirements and clinical implications. Eur J Immunol. 1998 Jun; 28(6):1894-901. PMID: 9645371.
      Citations: 3     Fields:    Translation:HumansCells
    100. Kim YH, Goodman C, Omessi E, Rivera V, Kattan MW, Boone TB. The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol. 1998 Mar; 159(3):972-6. PMID: 9474196.
      Citations: 12     Fields:    Translation:Humans
    101. Jerger J, Alford B, Lew H, Rivera V, Chmiel R. Dichotic listening, event-related potentials, and interhemispheric transfer in the elderly. Ear Hear. 1995 Oct; 16(5):482-98. PMID: 8654903.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    102. Safi HJ, Bartoli S, Hess KR, Shenaq SS, Viets JR, Butt GR, Sheinbaum R, Doerr HK, Maulsby R, Rivera VM. Neurologic deficit in patients at high risk with thoracoabdominal aortic aneurysms: the role of cerebral spinal fluid drainage and distal aortic perfusion. J Vasc Surg. 1994 Sep; 20(3):434-44; discussion 442-3. PMID: 8084037.
      Citations: 13     Fields:    Translation:Humans
    103. Crawford ES, Svensson LG, Hess KR, Shenaq SS, Coselli JS, Safi HJ, Mohindra PK, Rivera V. A prospective randomized study of cerebrospinal fluid drainage to prevent paraplegia after high-risk surgery on the thoracoabdominal aorta. J Vasc Surg. 1991 Jan; 13(1):36-45; discussion 45-6. PMID: 1987395.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    104. Mawad ME, Rivera V, Crawford S, Ramirez A, Breitbach W. Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. AJR Am J Roentgenol. 1990 Dec; 155(6):1303-7. PMID: 2122684.
      Citations: 12     Fields:    Translation:Humans
    105. Mawad ME, Rivera V, Crawford S, Ramirez A, Breitbach W. Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. AJNR Am J Neuroradiol. 1990 Sep-Oct; 11(5):987-91. PMID: 2121005; PMCID: PMC8334116.
      Citations: 15     Fields:    Translation:Humans
    106. Rivera VM. Multiple sclerosis. Is the mystery beginning to unfold? Postgrad Med. 1986 Jun; 79(8):217-32. PMID: 3520524.
      Citations:    Fields:    Translation:HumansCells
    107. Rivera VM, Meyer JS, Hata T, Ishikawa Y, Imai A. Narcolepsy following cerebral hypoxic ischemia. Ann Neurol. 1986 May; 19(5):505-8. PMID: 3717910.
      Citations: 4     Fields:    Translation:Humans
    108. Hannley M, Jerger JF, Rivera VM. Relationships among auditory brain stem responses, masking level differences and the acoustic reflex in multiple sclerosis. Audiology. 1983; 22(1):20-33. PMID: 6830528.
      Citations: 2     Fields:    Translation:Humans
    109. Rivera VM. Intraspinal steroid therapy. Neurology. 1981 Aug; 31(8):1060-1. PMID: 6894967.
      Citations: 1     Fields:    Translation:Humans
    110. Rivera VM, Grabois M, Deaton W, Breitbach W, Hines M. Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness. Arch Neurol. 1980 Apr; 37(4):201-3. PMID: 7362484.
      Citations: 2     Fields:    Translation:Humans
    111. Jankovic J, Rivera VM. Hereditary myoclonus and progressive distal muscular atrophy. Ann Neurol. 1979 Sep; 6(3):227-31. PMID: 534421.
      Citations: 10     Fields:    Translation:Humans
    RIVERA's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (493)
    Explore
    _
    Co-Authors (11)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _